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Abstract
Background: The development of metastases is a negative prognostic parameter for the clinical outcome of
breast cancer. Bone constitutes the first site of distant metastases for many affected women. The purpose of this
retrospective multicentre study was to evaluate if and how different variables such as primary tumour stage,
biological and histological subtype, age at primary diagnosis, tumour size, the number of affected lymph nodes as
well as grading influence the development of bone-only metastases.
Methods: This retrospective German multicentre study is based on the BRENDA collective and included 9625
patients with primary breast cancer recruited from 1992 to 2008. In this analysis, we investigated a subgroup of 226
patients with bone-only metastases. Association between bone-only relapse and clinico-pathological risk factors
was assessed in multivariate models using the tree-building algorithms “exhausted CHAID (Chi-square Automatic
Interaction Detectors)” and CART(Classification and Regression Tree), as well as radial basis function networks
(RBF-net), feedforward multilayer perceptron networks (MLP) and logistic regression.
Results: Multivariate analysis demonstrated that breast cancer subtypes have the strongest influence on the
development of bone-only metastases (χ2 = 28). 29.9 % of patients with luminal A or luminal B (ABC-patients) and
11.4 % with triple negative BC (TNBC) or HER2-overexpressing tumours had bone-only metastases (p < 0.001). Five
different mathematical models confirmed this correlation. The second important risk factor is the age at primary
diagnosis. Moreover, BC subcategories influence the overall survival from date of metastatic disease of patients with
bone-only metastases. Patients with bone-only metastases and TNBC (p < 0.001; HR = 7.47 (95 % CI: 3.52–15.87) or
HER2 overexpressing BC (p = 0.007; HR = 3.04 (95 % CI: 1.36–6.80) have the worst outcome compared to patients
with luminal A or luminal B tumours and bone-only metastases.
Conclusion: The bottom line of different mathematical models is the prior importance of subcategories of breast
cancer and the age at primary diagnosis for the appearance of osseous metastases. The primary tumour stage,
histological subtype, tumour size, the number of affected lymph nodes, grading and NPI seem to have only a
minor influence on the development of bone-only metastases.
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Background
Despite continual improvements achieved in the diagno-
sis and treatment of breast cancer (BC), 20 to 30 % of
patients with early breast cancer will face relapse and de-
velop potentially incurable distant metastases [1]. There-
fore, the spread of malignant cells to distant sites and
the growth of metastases is one of the most virulent at-
tributes of cancer.
Despite extensive research on the spreading of tumour
cells, a comprehensive understanding of the process of
breast cancer metastases, including tumour cell seeding,
tumour dormancy, and metastatic growth, is only partly
understood. A better knowledge of the pattern of meta-
static spread could help to adapt adjuvant therapies and to
personalize follow-up examinations of cancer patients.
The existing molecular and immunological approaches
of explanation for the spread of tumour cells and the
formation of metastases focus on the vascular infiltra-
tion, circulation, epithelial adherence and extravasation
of malignant cells. Moreover, the “seed and soil” hypoth-
esis firstly published by Stephen Paget et al. plays a de-
cisive role for description of the spread of tumor cells.
This theory describes the organ-preference patterns of
tumor metastasis as a product of favorable interactions
between cancer cells and specific organ microenviron-
ments [2, 3]. Considerable numbers of clinical studies
underline the great interest in this subject [4, 5]. These
explanatory models and clinical studies identified several
correlations between breast cancer subtypes and clinical
characteristics.
The bottom line of these studies is the unfavorable
prognosis of tumours that are triple negative or that
overexpress HER2. BC subtypes that express estrogen
and progesterone receptors are correlated with a positive
clinical outcome and the tendency to develop most likely
osseous metastases [6–8].
Altogether, bone is the first site of distant disease
in 25 to 40 % of women with advanced breast cancer.
Although patients with osseous metastases have signifi-
cantly better clinical outcome than women with visceral
or cerebral metastases [9], bone constitutes a site of para-
mount importance for the development of distant metas-
tases of breast cancer.
The establishment of metastases in the skeleton is based
on mutual interactions of breast cancer cells with the os-
seous microenvironment consisting of osteoblasts and os-
teoclasts. The process of bone destruction and resorption
and the release of growth factors by the last mentioned
cells promote adherence, survival and proliferation of
tumour cells. Therefore, bone destruction and growth of
tumour cells constitutes a vicious circle [10]. Remodeling
processes in the skeleton that take place at the time of
early breast cancer development and dissemination could
favour the growth of osseous metastases [11].
Considering these theories, several clinical and basic
studies have been performed to find target factors asso-
ciated with bone-specific distant recurrence of BC.
The International Breast Cancer Study Group analyzed
recurrence date in a study population of 6000 patients,
who were treated in seven adjuvant breast cancer trials
in order to figure out patients at high risk for bone me-
tastases [12]. Factors associated with increased rates of
osseous recurrence included higher numbers of involved
lymph nodes, larger tumour size and estrogen receptor
(ER) expression. Lipton et al. tried to identify a subset of
patients with breast cancer with a predilection to bone
as the first site of distant recurrence by using a serum
assay for the carboxyterminal peptide of type I collagen
(CTx), a marker for bone turnover released during bone
resorption [13].
Improving knowledge about the interaction of breast
cancer cells and bone environment could help to deter-
mine and to define a subgroup of women and subtypes of
breast cancer which have a high risk of developing osseous
metastases. Moreover, these findings could help to develop
personalized and tailored breast cancer therapy [13, 14].
In this retrospective study, we analysed the correlation
between the risk for the development of bone-only metas-
tases and different prognostic factors like primary tumour
stage, the biological and histological subtype, the age at
primary diagnosis, the tumour size, the number of affected
lymph nodes as well as the grading. We were able to
evaluate the importance of different clinical variables for
the development of osseous metastases und resolve some
apparent contradictions described in the literature.
Methods
The comprehensive database BRENDA has been de-
scribed in several publications [15, 16], and contains 886
patients with advanced breast cancer. The clinical data
and information were collected between 1992 and 2008.
Patients were diagnosed and treated at the Department
of Gynecology and Obstetrics at the University of Ulm
or in one of the 16 other certified breast cancer centers
of the BRENDA-study group. The primary end point of
this trial was the risk of the development of bone-only
metastases and the prognostic impact of different variables
like primary tumour stage, the biological and histological
subtype, age at primary diagnosis, tumour size, the number
of affected lymph nodes as well as the grading. Secondary
end points were metastasis-free survival (MFS) with focus
on bone as the only site of relapse and overall survival from
date of advanced breast cancer. For each patient included
in the study, a written consent form was obtained.
Study cohort
The study population is based on a subgroup of patients
of the BRENDA collective (n = 9625) comprising 886
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women with evidence of distant metastases. The follow
up was conducted for at least 10 years from date of pri-
mary diagnosis. In the study population of 886 women
226 (25.5 %) developed bone-only metastases within
10 years after primary diagnosis of breast cancer. Bone
metastases was defined as morphological detection of
metastases typical formations in the skeleton via medical
imaging [17].
For the study cohort, primary tumour stage, the bio-
logical and histological subtype, the age at primary diagno-
sis, the tumour size, the number of affected lymph nodes,
the Nottingham Prognostic Index (NIP) as well as the
grading of the tumour were analyzed separately in relation
to the risk of the appearance of bone-only metastases.
The TNM classification was used as published by the
UICC to define the primary tumour stage. Secondly, the
study cohort was split into two groups, women who
were older than 65 years (>65 years) or younger than
65 years (≤65 years). In terms of histological subtypes,
we set up three study groups: invasive ductal breast can-
cer, invasive lobular and others (comprising medullar,
tubular and mucinous breast cancer subtypes).
To define the biological breast cancer subtypes, the
cell proliferation marker Ki67 is currently used. As this
marker was not determined for the BRENDA database
we modified the St Gallen molecular subtypes as sug-
gested by Parise et al., von Minckwitz et al. and Lips et
al. We used the characteristics hormone receptor ex-
pression (HR), HER2 overexpression and tumour grade
(low = tumour grade of 1 or 2; high = tumour grade of 3)
instead: Luminal A is defined by HR positive, HER2
negative- and low tumor grade, luminal B HER2 negative
(luminal B/HER-) by HR positive,HER2 negative and
high tumor grade, whereas luminal B HER2 positive
(luminal B/HER2+) represents HR positiveHER2 positive.
The triple negative breast cancer (TNBC) is negative for
HR and HER2. The HER2-overexpressing subtype is de-
fined by negative HR and positive HER2 [18–21].
According to gene expression profiling (GEP), 71 % of
triple-negative tumours showed a basal-like phenotype
and 77 % of basal-like tumours showed a triple-negative
phenotype. Basal-like cancers are a heterogeneous cat-
egory comprising mainly infiltrating ductal carcinoma of
no special type. Medullary, atypical medullary, metaplas-
tic, secretory, myoepithelial, and adenoid cystic carcin-
omas of the breast also show a basal-like phenotype.
The Nottingham prognostic Index (NPI) was calculated
using the formula: NPI = [0.2 x S] + N + G. S is the
size of the index lesion in cm, N is the nodal status:
0 nodes = 1, 1–3 nodes = 2, 4+ nodes = 3 and G is the
grade of tumour: Grade I =1, Grade II =2, Grade III =3.
Nottingham Prognostic Score (NPS) was calculated using
NPI: NPI ≤ 3.4: low risk; NPI > 3.4 and ≤5.4: intermediate
risk and NPI > 5.4: high risk. For classifying the grading of
breast cancer, we applied the morphological assessment of
the degree of differentiation of breast cancer described by
Elston et al. [22]. Information on the time and site of first
distant metastases was obtained from physicians respon-
sible for follow-up care. Moreover, patients, as well as the
local death registries, answered questionnaires.
Statistical analysis
All categorical data were described using numbers and
percentages. Comparisons of categorical variables be-
tween groups were made by using χ2 tests. Quantitative
data were presented using median and range or mean
and standard deviations. Overall survival from the time
of metastases was defined as the interval between the
first distant metastases and death. If the patient was lost
to follow-up, data were censored at the date of the last
known contact. When no information was available, the
status was coded as missing data. Survival distributions
and median survival times were estimated using the
Kaplan–Meier product-limit method. The log-rank test
was used to compare survival rates. Further, the Cox
proportional hazards model was used to estimate the
hazard ratio and confidence intervals. The proportional
hazards assumption was assessed by including both the
product of the individual terms and time in the models.
To adjust for differing risk factor distributions between
groups, the multivariate Cox proportional hazards regres-
sion models were used. Furthermore, we used two tree-
building algorithms, “exhausted CHAID” (Chi-squared
Automatic Interaction Detector) and CART (Classification
and Regression Trees), with relapse to bone-only (yes or
no) as the dependent variable and breast cancer subtype
and other patient/tumour characteristics included as covar-
iates. These associations were further examined in multi-
variate models using radial basis function networks (RBF-
net), feedforward multilayer perceptron networks (MLP)
and logistic regression. An RBF-network is an artificial
neural network that uses radial basis functions as activation
functions. The Bayesian Information Criterion (BIC) deter-
mines the number of units in the hidden layer. The "best"
number of hidden units is the one that yields the smallest
BIC in the training data. We used normalized radial basis
functions as activation functions for the hidden layer,
which "links" the units in a layer to the values of units in
the succeeding layer. For the output layer, we used as acti-
vation function just the identity function; thus, the output
units are simply weighted sums of the hidden units. The
output of the network (bone-only metastases) is therefore
a linear combination of radial basis functions of the inputs
and neuron parameters. A multilayer perceptron (MLP) is
a feedforward artificial neural network model that maps
sets of input data onto a set of appropriate outputs (bone-
only metastases). An MLP consists of multiple layers of
nodes in a directed graph, with each layer fully connected
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to the next one. Except for the input nodes, each node is a
processing element (neuron) with a nonlinear activation
function. In our case, we used the hyperbolic tangent as ac-
tivation function for the units in the hidden and output
layer respectively. MLP utilizes backpropagation as super-
vised learning technique for training the network. To
evaluate the performance of the models, we used receiver
operating curves (ROC), as well as the predictiveness
curve, a plot of cumulative percentage of individuals to the
predicted risks.
Cumulative percentage indicates the percentage of indi-
viduals that have a predicted risk equal to or lower than
the risk value. Statistical analyses were two-sided and p-
values less than 0.05 were considered statistically signifi-
cant. We used R-3.20, IBM SPSS 22 and RapidMiner 6.
Results
Characteristics of the study cohort
We probed a study population of 9625 female breast
cancer patients. Our study cohort consisted of 886
(9.2 %) patients with confirmed metastatic breast cancer.
226 (25.5 %) women developed bone-only metastases
within 10 years after primary diagnosis of breast cancer.
The median age at primary diagnosis of the 226 patients
with bone-only metastases was 67.0 years (y) [range: 30-
93y] and at distant relapse 69y [range: 33-93y]. Nearly
50 % of the 226 (25.5 %) patients with bone-only metasta-
ses had a metastatic free survival of just 1 y [median
13 months; 95 % CI 7.4–18.6 months]. On the other side,
the maximum metastatic free survival (MFS) was 16.4 y,
but the percentage of patients with bone-only metastases
and MFS > 10 years was very small (1.8 %). For patients
with other sites of relapse, the maximum MFS was
11.8 years (Table 1).
Univariate and multivariate analysis examining factors
associated with bone-only-specific distant recurrence in
breast cancer
We could identify a highly significant difference in bone-
only metastases behaviour between invasive ductal and
invasive lobular/other subtypes of breast cancer. 35 % of
patients with lobular/other subtypes of breast cancer and
23 % with invasive ductal carcinoma had bone-only me-
tastases (p = 0.002). There was no significant difference
between lobular and other subtypes (p = 0.241).
In the next step, we analyzed whether the histological
subtype of breast cancer is still significant for the de-
velopment of bone-only metastases in a multivariate
analysis integrating subclasses of BC and histological
subtypes. This analysis revealed that breast cancer
subtype has the strongest influence on the development of
bone-only metastases (χ2 = 28). 29.9 % of patients with
luminal A or luminal B and 11.4 % with TNBC or
HER2-overexpressing tumours had bone-only metastases
(p < 0.001). The histological subtype is decisive for patients
with luminal A or luminal B (χ2 = 8). In this subclass,
27.0 % of patients with invasive ductal and 38.9 % with
lobular/other carcinomas had bone-only metastases
(p = 0.016) (Fig. 1). 10.3 % of the patients with TNBC
or HER2-overexpressing invasive ductal carcinomas had
bone-only metastases.
In addition, there is a highly significant (p < 0.001)
difference in tumour subclasses between various histo-
logical subtypes. 89.3 % of the patients with invasive
lobular carcinoma and 60.8 % with invasive ductal
carcinoma had luminal A or luminal B/HER2- tu-
mours. Patients with the invasive lobular carcinoma
had a significantly higher percentage of luminal A or
luminal B/HER2- tumours compared to patients with
ductal carcinoma (Fig. 2a).
Next, we analyzed the influence of age at date of pri-
mary diagnosis. Univariate analysis showed a highly sig-
nificant difference in bone-only metastases behaviour
between women younger than 65 years and women
older than 65 years (p < 0.001). Only 20.1 % of women
younger than 65 years developed bone-only metastases,
whereas 33.0 % of patients older than 65 years suffered
from bone-only metastases. Multivariate analysis together
with subtypes of BC illustrated that age is the second
strongest influence (χ2 = 17) after subtypes of BC (χ2 = 28).
In the subtypes of patients with luminal A or luminal B
BC, 23.6 % of patients younger than 65 and 38.3 % of pa-
tients older than 65 had bone-only metastases (p < 0.001).
Tumour size and nodal status were no significant factors
for bone-only metastases (both p = 1.0).
After age and histological subtype, we investigated
the influence of tumour grading. Univariate analysis
demonstrated a highly significant difference in bone-
only metastases occurrences between patients with G3-
tumours and G1 or G2-tumours (p = 0.001). 20.5 % of
the patients with G3-tumours and 31.1 % of the pa-
tients with G1/G2-tumours had bone-only metastases.
Applying multivariate analysis and integrating sub-
classes of BC demonstrates that subclasses are the only
significant prognostic factors for the development of
bone-only metastases. A partial explanation for this re-
sult is given by the fact, that grading is part of the def-
inition of subclasses. 36.5 % of the G3-patients but only
10.6 % of the G1/G2-patients were TNBC or had a
HER2 overexpression.
Further univariate analysis illustrated that the age at
primary diagnosis is significantly correlated with the histo-
logical subtype of BC. 8.8 % (82.1 %) of patients younger
than 65 years (≤65) and 15.5 % (71.8 %) of patients older
than 65 years (>65 years) at primary diagnosis developed
lobular (ductal) carcinoma (p = 0.001). However, there is
no significant difference between subcategories of BC and
age at primary diagnosis (p = 0.084) (Fig. 2b).
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Subcategories of breast cancer and age at primary
diagnosis are both important independent variables for
the development of bone-only metastases
Finally, we attempted to find out in a multivariate
analysis, which of the following primary tumour factors
(1) subcategories of BC (luminal A, luminal B/HER2-,
luminal B/HER2+, TNBC and HER2 overexpressing),
(2) histological subtypes, (3) age at primary diagnosis,
(4) tumour size, (5) number of affected lymph nodes,
(6) grading and (7) NPI are associated with bone-only-
specific distant recurrence in BC. We compared the
results of five different models: 1. Exhausted CHAID
(decision-tree algorithm), 2. CART (classification and
regression trees), 3. Radial Basis Function Network, 4.
Multilayer Perceptron and 5. Logistic Regression. The
decision-tree algorithms exhausted CHAID and CART
revealed that the subcategories of BC, age at primary
diagnosis and the histological subtypes were the three
significant factors associated with bone-only-specific
distant recurrence. Subcategories of BC has the stron-
gest influence (χ2 = 28), followed by age (χ2 = 17) at
primary diagnosis and histological subtypes (χ2 = 7).
There is a highly significant difference (p < 0.001) be-
tween patients with TNBC or HER-overexpressing BC
(11.4 % bone-only metastases) and patients with luminal
A or luminal B BC (29.9 % bone-only metastases).
However, there is no significant difference between the
subgroups luminal A, luminal B/HER2+ or luminal
B/HER2- (p = 0.395). Age has the second strongest
influence. In the subgroup of luminal A or luminal B
Table 1 Basic characteristics
patients with advanced breast cancer bone-only metastases p-value
Total yes no
886 226 (25.5 %) 660 (74.5 %)
Age at primary diagnosis
(in years)
mean: 61 (SD 14.2)
(median:62)
mean: 65 (SD 14.3)
(median:67)
mean: 60 (SD 13.9)
(median: 61)
0.03
Range: 22–96 Range: 30–93 Range:22–96
Metastatic free survival (MFS)
(in months)
mean: 25 (SD 27.7)
(median:18)
mean: 23 (SD 33.3)
(median:13)
mean: 26 (SD 25.4)
(median: 19)
0.03
Range: 0–197 Range: 0–197 Range:0–142
T-categories
(in absolut numbers (percent)
T1 283 (31.9) 72 (25.4) 211 (74.6) 0.385
T2 485 (54.7) 118 (24.3) 367 (75.7)
T3/T4 118 (13.3) 36 (30.5) 82 (69.5)
Menopausal status (dto.) premenopausal 204 (23.0) 37 (18.1) 167 (81.9) 0.026
perimenopausal 31 (3.5) 6 (19.4) 25 (80.6)
postmenopausal 649 (73.3) 182 (28.0) 467 (72.0)
unknown 2 (0.2) 1 (50.0) 1 (50.0)
Receptor staus (dto.) negative 210 (23.7) 24 (11.4) 186 (88.6) <0.001
positive or unknown 676 (76.3) 202 (29.9) 474 (70.1)
HER2/neu (dto.) negative or unknown 704 (79.5) 190 (27.0) 514 (73.0) 0.047
positive 182 (20.5) 36 (19.8) 146 (80.2)
Grading (dto.) 1 26 (2.9) 8 (30.8) 18 (69.2) 0.002
2 416 (47.0) 127 (30.5) 289 (69.5)
3 444 (50.1) 91 (20.5) 353 (79.5)
Nodal staus (dto.) nodal negative 268 63 (23.5) 205 (76.5) 0.716
1 < = N < = 3 198 49 (24.7) 149 (75.3)
3 < N < =10 198 49 (24.7) 149 (75.3)
N > 10 193 51 (26.4) 142 (73.6)
sub-categories (dto.) luminal A 352 (39.7) 115 (32.7) 237 (67.3) <0.001
luminal B/HER2- 221 (24.9) 62 (28.1) 159 (71.9)
luminal B/HER2+ 103 (11.6) 25 (24.3) 78 (75.7)
TNBC 131 (14.8) 13 (9.9) 118 (90.1)
HER2-overexpressing 79 (8.9) 11 (13.9) 68 (86.1)
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BC, 38.3 % of the patients older than 65 years and
23.6 % younger than 65 years had bone-only metasta-
ses (p < 0.001). In contrast to this, neither age nor
histological subtype were significant factors for TNBC or
HER2-overexpressing BC. In the subgroup of luminal A
or luminal B-patients who are younger than 65 years, we
found a significant difference (p = 0.032) between patients
with invasive lobular/other (35.1 % bone-only metastases)
and invasive ductal carcinoma (20.7 % bone-only metasta-
ses). If these patients were older than 65 years, CART re-
vealed grading as an additional important factor. In the
subgroup of luminal A or luminal B patients older than
65 years, 41.4 % of the patients with G1/G2 tumours and
33.0 % with G3 tumour had bone-only metastases, but this
result was no longer significant (p = 0.154; Bonferroni
adjusted chi-square test) (Fig. 3).
Next, we used two data mining algorithms: Radial
basis function (RBF) network and multilayer perceptron
(MLP). We calculated and compared two different risk
models: Risk model I included age at primary diagnosis,
tumour size, the number of affected lymph nodes, grad-
ing, the subcategories of breast cancer, the histological
subtypes and NPI. In contrast, risk model II consisted of
the subcategories of breast cancer and the age at pri-
mary diagnosis. Analysis demonstrated that there was no
significant difference between both risk models.
Subcategories of breast cancer and age at primary
diagnosis were both important independent variables.
Fig. 1 Multivariate Analysis (MA) demonstrates the strong interaction of BC subcategories with the dependent variable: bone-only metastasis.
Independent variables: subcategories of BC and BC histological subtypes. Dependent Variable: Bone-only metastasis
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The normalized importance of subcategories of breast
cancer was 100 % for RBF and MLP. For the age at pri-
mary diagnosis, the normalized importance was 49.7 %
for MLP and 45.9 % for RBF. The other variables seemed
to have only a minor influence on the development of
bone metastases. The area under the curve of the func-
tion generated by the RBF network was 0.64 and 0.66 in
the case of MLP (Fig. 4a and b).
In a further analysis, we calculated and compared two
binary logistic models as probabilistic classification
models to predict bone-only-specific distant recurrence
based on the same predictors as above. We could not,
again, find a significant difference between risk model
I and risk model II. Although risk model I contained
the additional variables: tumour size, number of af-
fected lymph nodes, grading, histological subtypes and
NPI, subcategories of breast cancer and age at pri-
mary diagnosis were again the only important inde-
pendent variables (Fig. 5).
Altogether, the five different models showed that the
subclasses of BC and the age at primary diagnosis were
the most important prognostic factors for bone-only
metastases. Tumour size and nodal status played no
significant part.
Fig. 2 a Subcategories of BC classified by histological subtypes. The analysis demonstrates that BC histological subtypes are associated (p < 0.001)
with distinct patterns of breast cancer subcategories. b Correlation of BC subcategories and age at primary diagnosis. Univariate analysis shows
that age at primary diagnosis is a significant parameter for classifying bone-only histological subtypes (p = 0.001). Independent Variable: age at
primary diagnosis. Dependent Variable: histological subtypes
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Subcategories of breast cancer are decisive parameters
for overall survival in patients with bone only analysis
Having clarified the importance of different variables for
the development of bone-only metastases, we analyzed
in a further step the effect of breast cancer subcategories
on overall survival from date of metastatic disease in
patients with bone-only metastases. Data were adjusted
by age. Cox Regression showed that luminal B/HER2+
and luminal B/HER2- subcategories had a significantly
worse OAS from date of metastatic disease compared
to patients with luminal A BC (Fig. 6). Patients with
TNBC (p < 0.001; HR = 7.47 (95 % CI: 3.52–15.87)
Fig. 3 The decision tree derived by exhausted Multivariate Analysis (CART) illustrates that subcategories of BC, age at primary diagnosis, histological
subtypes and grading are correlated with the appearance of bone-only metastases. Independent Variables: subcategories of BC, histological subtypes,
age at primary diagnosis, tumor size, number of affected lymph nodes and grading. Dependent Variable: bone-only metastasis
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and HER2 overexpressing BC (p = 0.007; HR = 3.04
(95 % CI: 1.36–6.80) had the worst outcome of patients
with bone-only metastases.
The development of bone-only metastases has changed
in a period of almost 20 years
In the final analysis, we focused on the risk of developing
bone-only metastases over a period of almost 20 years.
For this, we divided patients in two cohorts for the
decades 1992–2000 and 2001–2008 and analysed the risk
of the appearance of bone-only metastases separately. The
year 2000 was selected as intersection point as it coincides
with the introduction of new therapy standards. Univariate
analysis demonstrated that the year of primary diagnosis
was a significant parameter for classifying bone-only me-
tastases behaviour. 18.0 % of patients with primary diag-
nosis in 1992–2000 and 28.4 % with primary diagnosis in
2001–2008 had bone-only metastases (p = 0.001).
Fig. 4 a Radial Basis Function Network (RBF) demonstrates that subcategories of BC and age at primary diagnosis are the most important independent
variables for development of bone-only metastasis. The normalized importance of subcategories of BC is 100 % and of age at primary diagnosis 45 %.
Independent Variables: age at primary diagnosis, tumor size, nodal status, grading, subcategories of BC, histological subtypes, Nottingham prognostic
index. Dependent Variable: bone-only metastasis. b Multilayer Perceptron (MP) also demonstrates that subcategories of BC and age at primary diagnosis
are the most important independent variables for development of bone-only metastasis. The normalized importance of subcategories of BC is 100 %
and of age at primary diagnosis 62.9 %. Independent Variables: age at primary diagnosis, tumor size, nodal status, grading, subcategories
of BC, histological subtypes, Nottingham prognostic index. Dependent Variable: bone-only metastasis
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Discussion
Breast cancer with bone-only metastases is usually
thought to be associated with a relatively favourable
prognosis with median survival times in the range of
24–36 months compared with breast cancer with both
bone and other metastases or with non-bone sites of re-
lapse [13]. This result was already confirmed in one of our
previous studies: We had a median survival of 36.0 months
[95 % CI 26.2–45.8] [23]. Therefore, the primary aim of
the current study was to evaluate clinico-pathological risk
factors as possible prognostic factors for the development
of bone-only metastases. Univariate analysis showed
highly significant interactions between bone-only metasta-
ses and histological subtypes, subcategories of BC, age
and grading. Tumour size and number of affected lymph
nodes had no significant interactions.
Whereas the clinical outcome of patients affected by
breast cancer and bone metastasis has already been ex-
amined in several clinical trials [24, 25], other studies
focus on the risk factors for the development of bone
metastases. We could confirm the results published by
James et al., showing that bone metastases were signifi-
cantly more often associated with lower grade primary BC
than less differentiated tumours [26]. First site metastases
in the bone is more likely with lobular carcinoma than
with the invasive ductal carcinoma (NST). This is consist-
ent with the results of Purushotham et al. [27]. The same
authors showed a relationship between increasing age at
diagnosis and a reduction in risk of distant metastases to
bone and viscera. In our trial, the results were just the
Fig. 5 Logistic Regression Models (LRG) describes the relevance of
different variables for the development of bone-only metastases: black
line: risk model I, independent variables: Age at primary diagnosis,
subcategories of breast cancer red line: risk model II, independent
variables: Age at primary diagnosis, subcategories of breast cancer,
tumour size, nodal status, grading, Nottingham prognostic index.
The Predictiveness Curve is a plot of cumulative percentage of
individuals to the predicted risks [42]
Fig. 6 Overall Survival (OS) from date of metastatic disease of patients with bone-only metastases stratified by breast cancer subcategories. blue
line: Luminal A, green line: Luminal B/HER2 negative, yellow line: LuminalB/HER2 positive, violet line: HER2 overexpressing/hormone receptor
negative, red line: TNBC
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opposite. BC patients older than 65 years developed
bone-only metastases 1.5 times more often than younger
BC patients did. Of course, our study was restricted to
examining bone-only metastases.
One tool for estimating the risk of metastases is the
Nottingham Prognostic Index (NPI), as described above.
NPI is calculated using the tumour size, number of
involved lymph nodes and grading. Since tumour size
and number of involved lymph nodes had no significant
relation to bone-only metastases, grade was the only
remaining factor. As bone metastases are significantly
more common in lower grade primary BC, patients with
low risk NPI should have a higher percentage of bone-
only metastases compared to patients with intermediate
or high risk [17]. Indeed, 31 % of the low risk and 25 % of
the intermediate or high risk patients had bone-only me-
tastases, but this result was not significant.
Many publications describe the patterns of metastases
of BC. The bottom line of these studies is the high risk
of bone metastases for luminal A, luminal B/HER2+ or
luminal B/HER2- tumours. TNBC, basal like and HER2
positive tumours tend however, to develop visceral and
cerebral metastases [28–30]. These observations are in
accordance with our achieved results. However, our ana-
lysis goes beyond these univariate correlations. We were
able to determine the importance of these different vari-
ables for the development of bone-only metastases in
several multivariate analyses. There was a highly signifi-
cant correlation between subcategories of BC and bone-
only metastases. Only 11 % of ABC-patients with triple
negative or HER2-overexpressing tumours, but 30 % of
ABC patients with luminal A and luminal B had bone-only
metastases. Moreover, we could illuminate the importance
of the histological subtype of BC and its influence on
bone-only metastases, which is discussed contrarily in the
literature. Dixon et al. and Korhonen et al. could not detect
a significant difference between invasive lobular and inva-
sive ductal BC and the frequency of bone-only metastases
[31, 32]. Ferlicot et al., Jain et al. and Purushotham et al.
however demonstrated a higher frequency of primary
appearance of osseous metastases for the subgroup of
invasive lobular BC [27, 33, 34].
We could resolve this apparent contradiction by using
univariate and multivariate analysis. For univariate ana-
lysis, the histological subtype seems to be decisive. First,
histological subtypes were linked to distinct patterns of
breast cancer subcategories. 94 % of the patients with
metastasized lobular invasive carcinoma, but only 75 %
of the patients with ductal invasive carcinoma, had
luminal A or luminal B subtypes.
The triple negative or HER2 positive breast cancer
subtype, associated with a negative clinical outcome
[15], appeared to be rare among the invasive lobular
breast cancer subgroup. In contrast, 16 % of triple
negative and 10 % of HER2 positive BC belong to the
group of invasive ductal carcinomas. This finding is in
accordance with the higher percentage of bone-only me-
tastases in the subgroup of luminal A, luminal B/HER2
-, luminal B/HER2+ tumours as bone metastases is re-
lated to a better overall and recurrence free survival than
other sites of metastases [35].
Secondly, taking all clinico-pathological risk factors in
a multivariate model into consideration, subcategories of
BC were the most important variable followed by age at
primary diagnosis. 38 % of luminal A or B patients over
65 years had bone-only metastases. Histological subtypes
were no longer a significant prognostic factor in this
multivariate model.
In contrast to the significant correlation between
histological subtypes and subcategories of BC, we were
unable to find a significant correlation between BC sub-
categories and age at primary diagnosis; neither in the
subgroups of patients with bone-only metastases nor in
the whole group of BC-patients. This appears surprising,
as the patterns of subcategories are significantly different
with respect to age for the whole group of BC-patients.
For example, the percentage of patients with triple
negative or HER2-overexpressing BC decreased with
age: at primary diagnosis, 24 % of patients ≤35 years,
17 % between 35 and 65 years and 12 % >65 years had a
TNBC or HER2-overexpressing BC. These findings indi-
cate that biological mechanisms and biological subcat-
egories influence the development of metastases in
general and bone-only metastases in particular. This was
independent of the age at primary diagnosis and needs
to be further investigated.
To define the question of the risk factors for bone
metastases, we calculated and compared risks models;
one with all clinico-pathological factors and one with
only subcategories and age. We used three different
algorithms: there were no significant differences be-
tween the two models, independently of the algorithm
used. Subcategories of breast cancer and age at pri-
mary diagnosis seemed to be the most important risk
factors for developing bone-only metastases.
It is well known, that the risk of metastases development
increases with the presence of lymph-node metastases, a
larger sized primary tumour and loss of histopathological
differentiation (grade), which are the established breast
cancer prognostic markers [35]. None of these prognostic
parameters seemed to have an influence on the develop-
ment of bone-only metastases.
Finally, we investigated the effect of BC subcategories
and age on overall survival from date of distant relapse for
patients with bone-only metastases. Many publications
demonstrate the prognostic effect in terms of overall and
progression free survival for different subcategories of
breast cancer in general [29, 30, 36]. Our analysis showed
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similar results. Luminal A patients with bone-only metas-
tases had the best overall survival, while patients with
TNBC or HER2-overexpressing BC had the worst OAS.
The development of bone-only metastases in the time
period 2001–2008 compared to 1992–2000 seemed to
be surprising at first sight. There was a significantly
higher percentage of bone-only metastases in 2001–
2008 compared to 1992–2000, although, due to new
substances that reduce bone turnover [14, 37], we would
have expected a constant or even lower percentage of
bone-only metastases in the period 2000–2008. The
higher percentage of patients with bone-only metastases
could be explained by the growing number of older
women with metastasized breast cancer in the second
time period [38]. We demonstrated that patients tend to
develop bone-only metastases more frequently with in-
creasing age.
One limitation of this retrospective analysis is given
by the fact that the study group was recruited between
1992 and 2008. The risk of recurrence as well as the
patterns of metastases might have changed as thera-
peutic regimens have been modified and improved
since then. In the nineties, only about 60 % of hor-
mone receptor positive patients were treated with an
anti-hormonal therapy. Aromatase inhibitors were not
included in therapy of postmenopausal women. More-
over, the market approval of trastuzumab, pertuzumab
and T-DM1 has additionally improved the outcome
for patients with HER2 positive breast cancer [39, 40].
In terms of chemotherapeutic therapies, the discovery
of paclitaxel as well as the application of intensive
dose-dense chemotherapeutic regimes lead to a better
outcome and has maybe affected the patterns of re-
lapse [41].
Another limitation of this study might be undetected
subclinical metastases during staging and screening in-
vestigations conducted within the framework of tumour
after-care. On the other side, this statistical error affects
each breast cancer subtype equally. Moreover, tumour
follow up is based on clinical examinations. This ap-
proach has been conducted over the last 25 years and
proven effective.
A decisive advantage of this study is the comprehensive
documentation of every diagnosed metastatic lesion and,
therefore, a precise description of tumour follow up.
Conclusion
The bottom line of this analysis is the increasing risk for
the development of metastases in the presence of
lymph-node metastases, a larger sized primary tumour
and loss of histopathological differentiation (grade).
These factors are the established breast cancer prognos-
tic markers. None of these prognostic parameters seem
to have a dominant influence on the development of
bone-only metastases. Subcategories of breast cancer
and age at primary diagnosis were the only important
parameters for the appearance of bone-only metastases
in patients with advanced breast cancer. These findings
can help to personalize and individualize adjuvant ther-
apy and the tumour follow up examinations. Further re-
search in this field is necessary.
Availability of data and materials
Data will not be shared at the moment since these data
are used for further publications.
Ethical approval
The Ethics Committee of the University of Ulm, which
covers all participating breast cancer centers of the
BRENDA network, has approved this study and the
BRENDA project.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JD and MW developed the original idea for the manuscript and drafted the
manuscript. MW performed the statistical analysis; RK. LS and AW treated
and followed up the patients; TS, RS, MK, SH, WJ, MB and CB discussed the
data analysis; all authors read and approved the final manuscript.
Authors’ information
All authors except MW and MB are gynecological oncologist in Germany.
MW is professor and director of the eScience lab, Department of
Mathematics and Computer Science, University Bremen. MB is professor and
director of the Institute of Medical Biometry, Epidemiology and Informatics
(IMBEI), Johannes Gutenberg University Mainz. WJ is professor and
director of the department of Gynecology and Obstetrics, University
Ulm. AW is professor and director of department of Gynecology and
Obstetrics, University Würzburg. RK is professor and previous director of
the department of Gynecology and Obstetrics, University Ulm.
Acknowledgements
We express our thanks to the following persons for their contributions
to the BRENDA study: Karsten Gnauert (Ostalbklinikum, Aalen), Steffen
Fritz (Kreisklinik Biberach), Ulf Göretzlehner (Kreiskrankenhaus Ehingen),
Hans-Walter Vollert (Städt. Krankenhaus Friedrichshafen), Peter Jakob
Albert (Klinikum Heidenheim), Ricardo Felberbaum (Klinikum Kempten),
Andreas Zorr (Klinikum Konstanz), Felix Flock (Klinikum Memmingen), Erik
Schlicht (Stauferklinik, Mutlangen), Martina Gropp-Meier (Oberschwabenklinik
Ravensburg), Gerhard Bartzke (Kreiskrankenhaus Rottweil), Andreas Rempen
(Diakonie-Krankenhaus, Schwäbisch Hall), Edgar Schelble (Kreiskrankenhaus
Sigmaringen), Theodor Dinkelacker (Helfenstein-Klinik Geislingen), Andreas
Grüneberger (Oberschwabenklinik Wangen) and Thorsten Kühn (Städt.
Kliniken, Esslingen).
Funding source
This work was supported by the German Federal Ministry of Education and
Research (BMBF-Grant-01ZP0505).
Author details
1Department for Obstetrics and Gynecology, University of Würzburg Medical
School, Josef-Schneider-Str. 4, 97080 Würzburg, Germany. 2Department for
Obstetrics and Gynecology, University of Ulm Medical School, Prittwitzstr. 43,
89075 Ulm, Germany. 3Faculty of Mathematics and Computer Science,
University of Bremen, Universitätsallee GW1, 28359 Bremen, Germany.
4Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI),
University of Mainz, Obere Zahlbacher Str. 69, 55131 Mainz, Germany.
Diessner et al. BMC Cancer  (2016) 16:307 Page 12 of 13
Received: 7 September 2015 Accepted: 9 May 2016
References
1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of
chemotherapy and hormonal therapy for early breast cancer on recurrence
and 15-year survival: an overview of the randomised trials. Lancet. 2005;
365(9472):1687–717.
2. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;
359(26):2814–23.
3. Paget S. The distribution of secondary growths in cancer of the breast,
1889. Cancer Metastasis Rev. 1989;8(2):98–101.
4. Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-
Gutman L, Merling S, Svedman C, Rizel S, Lieberman N. The impact of the
21-gene Recurrence Score assay on clinical decision-making in node-
positive (up to 3 positive nodes) estrogen receptor-positive breast cancer
patients. Breast Cancer Res Treat. 2013;140(1):83–92.
5. Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, Ariad S,
Delgado B, Bayme M, Koretz M. The impact of the 21-gene recurrence score
assay on decision making about adjuvant chemotherapy in early-stage
estrogen-receptor-positive breast cancer in an oncology practice with a
unified treatment policy. Ann Oncol. 2011;22(11):2381–6.
6. Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic
effect of estrogen receptor status across age in primary breast cancer. Int J
Cancer. 2008;122(5):1089–94.
7. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE.
Risk factors for triple-negative breast cancer in women under the age of
45 years. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1157–66.
8. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Time to
disease recurrence in basal-type breast cancers: effects of tumor size and
lymph node status. Cancer. 2009;115(21):4917–23.
9. Imkampe A, Bendall S, Bates T. The significance of the site of recurrence to
subsequent breast cancer survival. Eur J Surg Oncol. 2007;33(4):420–3.
10. Mundy GR. Bone resorption and turnover in health and disease. Bone.
1987;8 Suppl 1:S9–16.
11. Pluijm G, Lowik C, Papapoulos S. Tumour progression and angiogenesis in
bone metastasis from breast cancer: new approaches to an old problem.
Cancer Treat Rev. 2000;26(1):11–27.
12. Diel IJ. Prognostic factors for skeletal relapse in breast cancer. Cancer Treat
Rev. 2001;27(3):153–7. discussion 159–164.
13. Lipton A. Should bisphosphonates be utilized in the adjuvant setting for
breast cancer? Breast Cancer Res Treat. 2010;122(3):627–36.
14. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M,
Gil M, Davies C, Burkinshaw R, et al. Safety of zoledronic acid and incidence
of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised
phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer.
Breast Cancer Res Treat. 2011;127(2):429–38.
15. Schwentner L, Wockel A, Konig J, Janni W, Ebner F, Blettner M, Kreienberg R,
Van Ewijk R. Adherence to treatment guidelines and survival in triple-
negative breast cancer: a retrospective multi-center cohort study with 9,156
patients. BMC Cancer. 2013;13:487.
16. Wockel A, Kurzeder C, Geyer V, Novasphenny I, Wolters R, Wischnewsky M,
Kreienberg R, Varga D. Effects of guideline adherence in primary breast cancer–a
5-year multi-center cohort study of 3976 patients. Breast. 2010;19(2):120–7.
17. Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, Lee JE, Nam SJ, Yang JH, Park
YH, et al. Implications of bone-only metastases in breast cancer: favorable
preference with excellent outcomes of hormone receptor positive breast
cancer. Cancer Res Treat. 2011;43(2):89–95.
18. Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2
Subtypes and a Surrogate Classification according to Tumor Grade and
Immunohistochemical Biomarkers. J Cancer Epidemiol. 2014;2014:469251.
19. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA,
Gerber B, Eiermann W, Hilfrich J, Huober J. Definition and impact of pathologic
complete response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.
20. Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary
summary of the consensus discussion. Breast Care (Basel). 2013;8(2):102–9.
21. Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S,
Wesseling J. Breast cancer subtyping by immunohistochemistry and histological
grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant
chemotherapy response. Breast Cancer Res Treat. 2013;140(1):63–71.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The
value of histological grade in breast cancer: experience from a large study
with long-term follow-up. Histopathology. 1991;19(5):403–10.
23. Schwentner L, Wolters R, Koretz K, Wischnewsky MB, Kreienberg R,
Rottscholl R, Wockel A. Triple-negative breast cancer: the impact of
guideline-adherent adjuvant treatment on survival–a retrospective multi-
centre cohort study. Breast Cancer Res Treat. 2012;132(3):1073–80.
24. Ahn SG, Lee HM, Cho SH, Lee SA, Hwang SH, Jeong J, Lee HD. Prognostic
factors for patients with bone-only metastasis in breast cancer. Yonsei Med
J. 2013;54(5):1168–77.
25. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT,
Theriault RL. Treatment outcome and prognostic factors for patients with
bone-only metastases of breast cancer: a single-institution retrospective
analysis. Oncologist. 2011;16(2):155–64.
26. James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, Robertson
JF. Bone metastases from breast carcinoma: histopathological - radiological
correlations and prognostic features. Br J Cancer. 2003;89(4):660–5.
27. Purushotham A, Shamil E, Cariati M, Agbaje O, Muhidin A, Gillett C, Mera A,
Sivanadiyan K, Harries M, Sullivan R, et al. Age at diagnosis and distant
metastasis in breast cancer–a surprising inverse relationship. Eur J Cancer.
2014;50(10):1697–705.
28. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH,
Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes.
J Clin Oncol. 2010;28(20):3271–7.
29. Park HS, Kim S, Kim K, Yoo H, Chae BJ, Bae JS, Song BJ, Jung SS. Pattern of
distant recurrence according to the molecular subtypes in Korean women
with breast cancer. World J Surg Oncol. 2012;10:4.
30. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD,
Castiglione-Gertsch M, Coates AS, Goldhirsch A, et al. Patterns of Recurrence
and outcome according to breast cancer subtypes in lymph node-negative
disease: results from international breast cancer study group trials VIII and
IX. J Clin Oncol. 2013;31(25):3083–90.
31. Dixon AR, Ellis IO, Elston CW, Blamey RW. A comparison of the clinical
metastatic patterns of invasive lobular and ductal carcinomas of the breast.
Br J Cancer. 1991;63(4):634–5.
32. Korhonen T, Kuukasjarvi T, Huhtala H, Alarmo EL, Holli K, Kallioniemi A,
Pylkkanen L. The impact of lobular and ductal breast cancer histology
on the metastatic behavior and long term survival of breast cancer
patients. Breast. 2013;22(6):1119–24.
33. Ferlicot S, Vincent-Salomon A, Medioni J, Genin P, Rosty C, Sigal-Zafrani B,
Freneaux P, Jouve M, Thiery JP, Sastre-Garau X. Wide metastatic spreading
in infiltrating lobular carcinoma of the breast. Eur J Cancer. 2004;40(3):336–41.
34. Jain S, Fisher C, Smith P, Millis RR, Rubens RD. Patterns of metastatic breast
cancer in relation to histological type. Eur J Cancer. 1993;29A(15):2155–7.
35. Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G,
Puglisi F. Pattern of metastasis and outcome in patients with breast cancer.
Clin Exp Metastasis. 2015;32(2):125–33.
36. Colzani E, Johansson AL, Liljegren A, Foukakis T, Clements M, Adolfsson J,
Hall P, Czene K. Time-dependent risk of developing distant metastasis in
breast cancer patients according to treatment, age and tumour
characteristics. Br J Cancer. 2014;110(5):1378–84.
37. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S,
Smith I, Ottestad L, Kanis J. Reduction in bone relapse and improved
survival with oral clodronate for adjuvant treatment of operable breast
cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13.
38. Turner N, Zafarana E, Becheri D, Mottino G, Biganzoli L. Breast cancer in the
elderly: which lessons have we learned? Future Oncol. 2013;9(12):1871–81.
39. Diessner J, Bruttel V, Becker K, Pawlik M, Stein R, Hausler S, Dietl J,
Wischhusen J, Honig A. Targeting breast cancer stem cells with HER2-
specific antibodies and natural killer cells. Am J Cancer Res. 2013;3(2):211–20.
40. Diessner J, Bruttel V, Stein RG, Horn E, Hausler SF, Dietl J, Honig A, Wischhusen J.
Targeting of preexisting and induced breast cancer stem cells with trastuzumab
and trastuzumab emtansine (T-DM1). Cell Death Dis. 2014;5:e1149.
41. Untch M, Mobus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N,
Werner C, Lebeau A, Schneeweiss A, et al. Intensive dose-dense compared
with conventionally scheduled preoperative chemotherapy for high-risk
primary breast cancer. J Clin Oncol. 2009;27(18):2938–45.
42. Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y.
Integrating the predictiveness of a marker with its performance as a classifier.
Am J Epidemiol. 2008;167(3):362–8.
Diessner et al. BMC Cancer  (2016) 16:307 Page 13 of 13
